Background {#Sec1}
==========

The issue of malignancy risk with tumour necrosis factor inhibitor (TNFi) therapy is complex. Chronic inflammation may promote tumorigenesis \[[@CR1]\], and TNF has been demonstrated to both promote and inhibit tumour development in animal models depending on dose and biological conditions \[[@CR2]\]. A systematic review of adalimumab and infliximab randomised controlled trials in rheumatoid arthritis (RA) patients reported a significantly higher malignancy risk compared with placebo \[[@CR3]\]. Subsequent systematic reviews, which have included etanercept, certolizumab and golimumab trials, have shown no increased risk of invasive cancer \[[@CR4]--[@CR9]\].

While several groups have demonstrated an increased risk of lymphoma with TNFi therapy \[[@CR10]--[@CR12]\], which may just reflect the known increased risk in RA \[[@CR13], [@CR14]\], observational studies have generally reported no increased risk of malignancy overall \[[@CR10], [@CR11], [@CR15]--[@CR20]\]. A 2011 systematic review of prospective observational studies supported these findings (pooled estimate of overall risk of malignancy 0.95, 95 % CI 0.85-1.05 compared with RA TNFi-naïve controls), although the risk of non-melanoma skin cancer (NMSC) was increased (pooled estimate of risk 1.45, 95 % CI 1.15-1.76) \[[@CR21]\]. A more recent systematic review examining the safety of biologic therapy included 49 prospective observational studies but was unable to pool data due to multiple sources of heterogeneity \[[@CR22]\]. Based upon findings from individual studies they concluded that TNFi exposure is not associated with an increased overall risk of malignancy, lymphoma or NMSC but may be associated with a slight increased risk of melanoma based upon a single study \[[@CR23]\].

In observational studies assessing risk of therapy the ideal comparator group should be identical to the study population in all ways apart from the intervention being evaluated. Outside the realms of randomised trials it is difficult to assemble such a group, and it is necessary to recognise limitations of different approaches. Prior investigators have compared the risk of malignancy in TNFi-treated RA patients with the general population \[[@CR10], [@CR11], [@CR15]--[@CR19]\], biologic-naïve RA cohorts \[[@CR16], [@CR17]\], and cohorts that include pre-TNFi person-years in the comparator group \[[@CR10], [@CR15]\]. Each of these comparison groups has potential differences compared to TNFi-treated RA patients, which may bias risk estimates. These include presence of rheumatic disease, disease activity, comorbidity and underlying malignancy risk. For instance, comparing malignancy risk in TNFi-treated RA patients with the general population measures not only the effect of TNFi therapy but also the effect of having RA. Comparing malignancy risk in TNFi-treated RA patients with biologic-naïve RA patients can partially account for the effect of RA, however confounding by indication can occur because TNFi-treated RA patients tend to have more severe disease than biologic-naïve RA patients. Including pre-TNFi person years (in individuals who subsequently commence TNFi therapy), can balance the groups in terms of disease severity, but separate biases may be introduced.

Because a history of malignancy can be a relative contra-indication for TNFi therapy, patients who are ultimately treated with a TNFi are likely to have a low incidence of malignancy in their pre-TNFi person years. This low incidence of malignancy in the comparator group can inflate the estimated malignancy risk in the TNFi-exposed group. Finally, while a number of biases and sample size issues could mask a true malignancy risk related to biologic therapy, alternative possibilities could be that there is no significant increased risk or that biologic therapy could be protective given the reduction in chronic inflammation and immune overactivity and the fact that TNF can both promote and prevent tumour formation through various complex mechanisms \[[@CR24]\].

The aim of this study was to assess the risk of malignancy with TNFi therapy in a cohort of Australian RA patients. Australia has the highest risk of melanoma in the world \[[@CR25]\], and a previous Australian study found a three-fold increased risk of melanoma in RA patients treated with methotrexate compared with the general population \[[@CR26]\]. We therefore also assessed the risk of malignancy in a biologic-naïve group of RA patients to examine the relative contribution of the RA disease process and background RA treatments on malignancy risk.

Methods {#Sec2}
=======

Setting {#Sec3}
-------

In Australia, government-subsidised treatment with biological disease modifying anti-rheumatic drugs (bDMARDs) is subject to strict criteria. These criteria have changed over time, but include inadequate response to at least two traditional DMARDs (one of which must be methotrexate unless contraindicated) over a period of 6 months, a tender and swollen joint count of greater than 20 joints (or 4 large joints) and elevated inflammatory markers. These criteria limit bDMARD therapy to patients with highly active and treatment-resistant RA. Up until November 2007 TNFi therapy was the mandatory first choice of bDMARD unless absolute contra-indications were present.

Australian Rheumatology Association Database (ARAD) design and data collection {#Sec4}
------------------------------------------------------------------------------

The structure, governance and content of ARAD have been described previously \[[@CR27]--[@CR30]\]. Initiated in 2001, ARAD is a voluntary registry that collects longitudinal health outcomes data from Australian patients with inflammatory arthritis. Most participants enrol when they commence biologics. Enrolment is also encouraged for those not starting biologic drugs but active targeting of these patients has only occurred on an ad hoc basis. Based on residential postcode, demographic and clinical characteristics participants appear to be nationally representative, with 246 (79 %) rheumatologists from all states and territories having contributed patients \[[@CR28]\].

ARAD has received ethical approval from committees and organisations across Australia. All participants provide written permission to be contacted by ARAD investigators and written informed consent to participate in the registry and the associated linkages.

At patient enrolment details of diagnosis, disease status data (ESR, CRP and joint count) and the bDMARD prescribed (if applicable) are obtained from the treating rheumatologist. All ARAD participants complete detailed entry and six-monthly follow-up questionnaires (paper-based or online). Data collected from the participants include: demographic details, disease duration and severity, self-reported past and current medical history including malignancies and other chronic conditions, use of anti-rheumatic drugs including the date commenced, smoking and alcohol history, Assessment of Quality of Life (AQoL) \[[@CR31]\] and arthritis-specific disability assessed by the Health Assessment Questionnaire (HAQ) \[[@CR32]\]. In the event of missing or ambiguous data or reporting of a significant event such as malignancy, ARAD staff contact the patient and the rheumatologist and/or other treating doctor to verify the data.

For the purpose of this study, ARAD participants were eligible if they had rheumatologist-diagnosed RA and had enrolled in ARAD prior to 25 October 2010 (the analysis cut-off date). Participants were divided into two mutually exclusive groups: participants who were biologic-naïve for the entire duration of observation, and participants who commenced a TNFi (etanercept, adalimumab or infliximab) as their first line biologic therapy. Our dataset predated subsidised prescription of certolizumab and golimumab in Australia. Patients who commenced a non-TNFi biologic as first line therapy (*n* = 5) were excluded. Baseline characteristics, medical history, HAQ and AQoL were extracted from the questionnaire completed at ARAD entry. Some questions relating to baseline descriptive variables and comorbidity were only added to the baseline questionnaire in January 2006 and so were unavailable for participants who completed their baseline questionnaire prior to this time.

Ascertainment of malignancy {#Sec5}
---------------------------

The National Cancer Statistics Clearing House (NCSCH) collates details of all malignancies occurring in Australia apart from NMSCs \[[@CR33]\]. Notification of malignancy to the state-based cancer registries has been mandatory in Australia since 1982. The state-based registries send identified data to the NCSCH for aggregation at a national level. The International Classification of Diseases, 10th Revision (ICD-10) is used to code site of malignancy. The ARAD patient database was linked with the NCSCH in July 2010 to ascertain all invasive malignancies in ARAD participants. At the time of linkage the NCSCH was complete from 1982 to 2007 and therefore we were able to ascertain all malignancies that occurred in ARAD participants from the time of their enrolment. The date of diagnosis of malignancy as recorded in the NCSCH was used in the analysis. Self-reported malignancies occurring after 31 December 2007 and verified by the treating doctor or pathology report were also included in the analysis with the date of diagnosis as the date of the doctor verification or the histology report.

Data analysis {#Sec6}
-------------

Person-years for biologic-naïve patients were calculated from the date of enrolment in ARAD until death or analysis cut-off date (25 October 2010). Person years of exposure to TNFis began at either the start date of the therapy or enrolment in ARAD (whichever was later) and continued until death or analysis cut-off date. Person-years prior to the commencement of TNFi were calculated for the TNFi-exposed group from enrolment in ARAD to the start date of the first TNFi. Patients taking a non-TNFi as first line biologic were excluded.

Standardised incidence ratios (SIRs) were used to compare the incidence of malignancy in biologic naïve and the TNFi-exposed ARAD participants with incidence in the Australian general population using the site-, age- and sex-specific rates by calendar year. Malignancy incidence in TNFi-exposed participants was compared with that in biologic naive participants with rate ratios calculated using the Mantel-Cox method with significance assessed using the log-rank test of the respective 'time to malignancy' distributions adjusted for age, sex, calendar year, smoking status, prior malignancy and methotrexate use. All data were analysed using Stata 11 \[[@CR34]\].

Results {#Sec7}
=======

There were 2957 RA patients eligible for study inclusion; 803 were biologic-naïve and 2154 had received TNFi therapy (first-line therapy: etanercept (*n* = 1129, 54 %), adalimumab (*n* = 829, 38 %), infliximab (*n* = 150, 7 %)). The characteristics of the biologic naïve group at entry to ARAD and the TNFi-exposed group at commencement of therapy are shown in Table [1](#Tab1){ref-type="table"}. Those starting TNFi as a first biologic therapy were younger, had more active disease as indicated by higher median joint count and CRP (but not ESR), greater prior use of DMARDs, including methotrexate and prednisolone, and higher disability and lower quality of life as indicated by higher HAQ and AQoL scores respectively. Prior malignancies were less commonly reported (3.3 % compared with 7.6 %).Table 1Demographic and clinical details of RA participantsBiologic-naïve patients^(a)^TNFi-treated patients^(b)^*p*-value*n* = 803*n* = 2154Female, n (%)567 (70.6)1582 (73.4)0.12\*Age in yrs, mean (SD)61.2 (12.3)55.6 (125)\<0.001\*\*Rheumatoid factor positive^(c)^, n (%)465/547 (85.0)1073/1326 (80.9)0.04\*No. of prior DMARDs, mean (SD)2.5 (1.8)4.0 (2.0)\<0.001\*\*Ever used methotrexate, n (%)614 (76.5)1851 (85.9)\<0.001\*Ever used prednisolone, n (%)452 (56.3)1899 (88.2)\<0.001\*HAQ score, mean (SD)1.16 (0.79)1.37 (0.73)\<0.001\*\*(range 0--3, 0 = no disability)AQoL score, mean (SD)0.53 (0.27)0.49 (0.24)\<0.001\*\*(range 0--1, 1 = full health)Joint count, median (range)14.5 (0, 59) (n = 286)24 (0, 72) (n = 906)\<0.001\*\*\*ESR mm/h, median (range)26 (1, 129) (n = 263)29 (0, 134) (n = 834)0.07\*\*\*CRP mg/L (median, range)8.5 (0.4, 161) (n = 264)17 (0.1, 206) (n = 836)\<0.001\*\*\*Current smoker, n (%)90/776 (11.6)300/2111 (14.2)0.07\*Years since RA diagnosis, mean (SD)13.0 (11.3)13.7 (10.5)0.12\*\*Prior malignancies^(d)^, n (%)61 (7.6 %)72 (3.3 %)\<0.001\*^(a)^ data from time first entered into registry unless otherwise indicated; ^(b)^ data from time first commenced TNFi treatment; ^(c)^ data incomplete: n is shown in table; ^(d)^ verified malignancies (excluding NMSC and in-situ cancers) recorded prior to commencement of the study period. *HAQ* health assessment questionnaire, *AQoL* assessment of quality of life; *ESR* erythrocyte sedimentation rate, *CRP* C-reactive protein.\* *p*-value from Chi-squared test; \*\* *p*-value from *t*-test; \*\*\* *p*-value from Wilcoxon Rank Sum test

Follow up was 5752 and 1682 person-years for TNFi-exposed and biologic-naïve patients respectively. Forty-four malignancies were reported in the TNFi-exposed group and 32 in the biologic-naïve group. The overall malignancy risk for biologic-naïve participants was comparable to that expected on the basis of population rates but, on examination of site specific cancers, these patients had an elevated risk of melanoma (Observed = 5, Expected = 1.84; SIR 2.72 (95 % CI 1.13 to 6.53)) and lung cancer (Observed = 6, Expected = 2.41; SIR 2.49 (95 % CI 1.12 to 5.53)) (Table [2](#Tab2){ref-type="table"}). The overall malignancy risk among TNFi-treated RA patients was not elevated in comparison with the general population (Table [2](#Tab2){ref-type="table"}), but there was an increased risk of melanoma (Observed = 10, Expected = 4.92; SIR 2.03 (95 % 1.09 to 3.78)) and a reduced risk of colorectal cancer (Observed = 1, Expected = 7.75; SIR 0.13 (95 % CI 0.02 to 0.92)) in these patients.Table 2Risk of cancer in biologic-naïve and TNFi-treated RA patients compared with the Australian general population, and relative risk in the TNFi treated patients compared to biologic naïve patientsRisk of cancer in biologic-naïve RA patients compared with the general populationRisk of cancer in TNFi-treated patients compared with the general populationRelative risk (95 % CI) of cancer in TNFi-treated RA patients compared with biologic-naïve RA patientsSiteOESIR (95 % CI)OESIR (95 % CI)RR (95 % CI)^b^All invasive cancers3223.381.37 (0.97, 1.94)4456.780.77 (0.58, 1.04)0.65 (0.37, 1.17)Melanoma51.842.72 (1.13, 6.53)104.922.03 (1.09, 3.78)0.54 (0.12, 2.40)Lung62.412.49 (1.12, 5.53)45.230.77 (0.29, 2.04)0.24 (0.05, 1.17)Lymphoid cancers^a^11.490.67 (0.09, 4.76)63.541.69 (0.76, 3.77)4.01 (0.18, 88.19)Colorectal23.410.59 (0.15, 2.35)17.750.13 (0.02, 0.92)0.06 (0.001, 3.28)Prostate53.381.48 (0.62, 3.55)77.710.91 (0.43, 1.90)1.21 (0.33, 4.45)Female breast53.321.51 (0.63, 3.62)410.290.39 (0.15, 1.04)0.17 (0.03, 0.95)*TNFi* tumour necrosis factor inhibitor, *RA* rheumatoid arthritis, *SIR* standardised incidence rate, *NHL* non-Hodgkin's lymphoma; ^a^Lymphoid cancers includes all leukaemias and lymphomas, *RR* relative risk; ^b^adjusted for age, sex, calendar year, smoking status, methotrexate use and prior malignancy

When the TNFi-treated RA patients were compared with the biologic-naïve RA cohort there were no significant differences in malignancy risk overall or for specific cancer sites. (Table [2](#Tab2){ref-type="table"}). No difference in risk of melanoma was found between groups (RR 0.54 (95 % CI 0.12 to 2.40)).

In the analysis comparing malignancy risk in patients unexposed to biologics and including the biologic-naïve group plus pre-TNFi person years of observation for those who later commenced TNFi treatment, there was no overall increased risk of malignancy compared with the Australian population but as with the previous comparison, the melanoma and lung cancers risks were elevated (Table [3](#Tab3){ref-type="table"}). Adding the pre-TNFi person years of observation into the biologic-naïve comparator group did not appreciably alter the RRs for all invasive cancers or for specific sites when comparing malignancy risk to the TNFi-treated RA patients (Table [3](#Tab3){ref-type="table"}).Table 3Risk of cancer in biologic-naïve RA patients (including TNFi treated patients prior to TNFi exposure) compared with the general population, with relative risk in the TNFi treated patients compared to biologic naïve patientsRisk of cancer in biologic-naïve RA patients (including TNFi treated patients prior to TNFi exposure) compared with the general populationTNFi-treated patients compared with no previous exposure to biologicsSiteOESIR (95 % CI)RR (95 % CI) ^b^All invasive cancers3324.861.33 (0.94, 1.87)0.70 (0.39, 1.25)Melanoma51.972.54 (1.06, 6.11)0.68 (0.16, 2.87)Lung62.552.35 (1.06, 5.24)0.26 (0.05, 1.27)Lymphoid cancers^a^11.580.63 (0.09, 4.49)4.03 (0.18, 89.28)Colorectal23.60.56 (0.14, 2.22)0.19 (0.003, 13.94)Prostate53.611.39 (0.58, 3.33)1.20 (0.33, 4.40)Female breast53.581.40 (0.58, 3.36)0.20 (0.04, 1.06)*TNFi* tumour necrosis factor inhibitor, *RA* rheumatoid arthritis, *SIR* standardised incidence rate, *NHL* non-Hodgkin's lymphoma; ^a^Lymphoid cancers includes all leukaemias and lymphomas; *RR* relative risk; ^b^ adjusted for age, sex, calendar year, smoking status, methotrexate use and prior malignancy

Discussion {#Sec8}
==========

The incidence of malignancy was low in this cohort of RA patients. We found no overall increased malignancy risk when TNFi-treated RA patients were compared with the general population or with biologic-naïve RA patients, a result that is consistent with numerous previously reported observational studies \[[@CR10]--[@CR12], [@CR15]--[@CR21]\]. While the risk of female breast cancer was not reduced in TNFi-exposed RA patients in comparison with the general population, we did observe a reduced relative risk of female breast cancer in TNFi-treated RA patients compared with RA patients never exposed to biologics without (but not with) inclusion of the pre-TNFi person years of observation of the TNFi-treated RA patients in the biologic-naïve comparison group.

A reduced risk of female breast cancer in RA in comparison with the general population has previously been demonstrated in a number of studies \[[@CR18], [@CR19], [@CR35]--[@CR37]\]. In keeping with our findings, a recent study that comprised biologic-naïve RA patients recruited to the British Society for Rheumatology Biologics Register from 2002 to 2009 found no difference in risk in comparison with the general population (SIR 1.07 (95 % CI 0.72 to 1.52) \[[@CR38]\]. On the other hand, a reduced risk of breast cancer associated with TNFi exposure has been noted in a large observational study of RA patients that used a propensity score with relevant covariates and cohort trimming to improve the balance between DMARD cohorts \[[@CR39]\]. They identified a reduced adjusted risk of breast cancer with TNFi exposure compared with methotrexate (Hazard Ratio 0.09 (95 % CI 0.02 to 0.39). In keeping with the results from our study, data from the British, German and Swedish registries have also suggested a reduced risk of breast cancer associated with TNFi exposure \[[@CR18], [@CR37], [@CR40]\]. Mercer et al. noted a non-statistically significant reduction compared with biologic-naïve patients \[[@CR40]\]; while both Askling et al. and Strangfeld et al. noted a reduced risk in both TNFi-naïve and TNFi-exposed RA patients compared with the general population \[[@CR18], [@CR37]\]. As noted by Mercer et al., it is biologically plausible that TNF inhibition may slow or prevent breast cancer progression \[[@CR40]\], although a phase 2 study of etanercept did not find any objective disease response in people with metastatic breast cancer \[[@CR41]\].

While we did not find an increased risk of melanoma as a result of TNFi exposure, we did find an increased risk of melanoma in comparison with the general population in both biologic-naïve and TNFi-exposed patients (with or without including pre-TNF exposure years of TNFi-treated patients). These findings are consistent with a previous study that reported an increased the risk of melanoma in RA patients treated with methotrexate in an Australian cohort study (SIR 3.0, 95 % CI 1.2, 6.2) \[[@CR26]\]. The majority of patients in both the biologic naïve (80.2 %) and TNFi-exposed groups (96.9 %) were exposed to methotrexate in our study. Taken together, these observations suggest that RA status, and possibly methotrexate exposure related to RA status, may be responsible for this observed increased melanoma risk.

Several observational studies have evaluated the risk of melanoma in TNFi-treated RA patients and have reported conflicting results. In a comparison of RA patients from the National Data Bank with the US general population, Wolfe et al. reported an elevated risk of melanoma in the RA group overall (SIR 1.7, 95 % CI 1.3-2.3), and a non-significant elevated risk of melanoma in association with biologic therapy (OR 2.3, 95 % CI 0.9-5.4) \[[@CR19]\]. In contrast, a nationwide population based prospective cohort study from Sweden revealed no increased risk of melanoma in biologic-naïve RA patients compared with the general population (Hazard Ratio (HR) 1.2, 95 % CI 0.9-1.5), whereas their comparison between TNFi-treated patients and the biologic naïve cohort suggested an association between TNFi treatment and invasive melanoma (HR 1.5, 95 % CI 1.0-2.2) \[[@CR23]\].

The risk of melanoma in RA patients not taking biologic agents compared with the general population was recently reviewed by Perkins et al. \[[@CR42]\]. Eleven studies were identified from Sweden (*n* = 3), the USA/Canada (*n* = 3), Denmark, Scotland, Australia, Taiwan and Spain. The SIRs for melanoma in these studies ranged from 0.7-3.8, with the highest risks in Australia and Spain (SIR 3.8). The pooled analysis gave rise to a SIR of 1.01 (95 % CI 0.93-1.10), suggesting no increased risk. A more recent UK study of malignancy in RA patients receiving non-biologic DMARD therapy compared with the general population reported a SIR of 2.05 (95 % CI 0.94-3.90) for melanoma \[[@CR38]\]. Data regarding exposure to specific medications such as methotrexate, genetic background including skin colour and relative ultraviolet light exposure was not able to be considered in these analyses but could be important for melanoma risk in particular.

A reduced risk of colorectal cancer in RA patients has been consistently reported \[[@CR36]\], postulated to be related to non-steroidal anti-inflammatory drug use \[[@CR43]\]. However, in keeping with our data, some studies have not reported a reduced risk in biologic naïve RA patients compared with the general population \[[@CR38]\]. We found a reduced risk of colorectal cancer in TNFi-treated patients in comparison to the general population but the risk was not reduced in comparison with biologic-naïve patients. This is compatible with some studies that have reported non-significant reductions in TNFi-treated patients compared with the general population \[[@CR18], [@CR37], [@CR40]\]. However compared with biologic-naïve RA patients, Dreyer et al. reported an increased risk of colorectal cancer with TNFi exposure (Hazard ration 2.52 (95 % CI 1.11 to 11.15) \[[@CR20]\]. Further investigation is required to clarify the true risk of colorectal cancer with TNFi treatment.

Our finding of an increased risk of lung cancer in biologic-naïve RA patients compared with the general population is consistent with previous studies (e.g. \[[@CR16]\]) . However, similar to other registry studies \[[@CR19], [@CR40]\], we did not find an increased risk of lung cancer related to TNFi exposure.

The comparison between the TNFi-exposed cohort and the 'biologic-naïve' RA patients ensures that both groups have RA as an underlying disease state, although the TNFi-exposed group are likely to have more severe and/or active disease. The comparison between the TNFi-exposed cohort and the biologic-naïve cohort plus the pre-TNFi person-years of the TNFi-exposed RA patients is likely to have more balanced groups in terms of RA severity and increases the power of the analysis by increasing the person years in the comparator group. However inclusion of the pre-TNFi person-years of the TNFi-exposed RA patients did not appreciably change our results.

Other observational studies have used different comparator groups to investigate malignancy risk with TNFi therapy including the general population, a separate cohort, and a biologic-naïve cohort with and without pre-TNF exposure years. This may account for some of the observed differences between studies. Comparison with the general population fails to account for possible confounding due to factors related to the disease or its management. RA patients taking non-biologic DMARDs have been reported to have different rates of some cancers compared with the general population \[[@CR36], [@CR38]\], and therefore comparisons of TNFi treated patients with the general population must take this into consideration. Our finding in relation to melanoma risk is an example of this. Choosing a separate, biologic-naïve cohort also has potential for selection bias as these patients tend to have lower disease activity and different rates of concurrent and/or prior DMARD use than TNFi-treated patients. On the other hand, combining pre-TNFi years with a separate biologic-naïve cohort may also be prone to selection bias if patients are less likely to be prescribed TNFi if they have had a previous malignancy (irrespective of disease activity).

Although a history of malignancy was not an absolute contraindication to prescribing TNFi therapy in Australia when these drugs were first introduced, TNFi-treated patients were less likely to have had a prior malignancy (Table [1](#Tab1){ref-type="table"}), suggesting clinicians may have been wary of prescribing TNFi to people with a prior history of malignancy. This concern appears to have diminished over time as evidence about the long-term safety of TNFi accumulates, although current recommendations continue to advise avoidance of TNFi in people with a history of malignancy within the prior five years \[[@CR44]\].

Strengths of our study include national representation of patients from most rheumatologists, and over 7500 patient years of follow up. Linkage of the ARAD database with the NCSCH ensures virtual complete ascertainment of malignancies between 1982 and the end of 2007. Between 1 January 2008 and 25 October 2010 (analysis cut off) we relied upon patient-reported malignancies that were subsequently verified by the treating doctor and/or histology reports. Under-ascertainment of malignancies during this period is possible, however both groups of RA patients were subject to these conditions making systematic bias unlikely.

The study was limited by the fact that data for the entire Australian TNFi-treated RA population are unavailable, and thus we are unable to determine whether our TNFi-treated cohort is representative of Australian TNFi-treated patients in general. In addition, we acknowledge that our analyses may be compromised by immortal time bias whereby patients already diagnosed with cancer do not enrol in ARAD. We have no way of assessing or addressing this bias.

Our patient numbers were not sufficient to analyse data for each TNFi separately hence we have presented pooled data. As our dataset predated subsidised prescription of certolizumab and golimumab in Australia our results may or may not be generalisable to these anti-TNF therapies. Furthermore, we do not have sufficiently detailed information on concomitant medication use, including precise duration of therapy and dose, so cannot explore in detail the effect of methotrexate and other DMARDs on malignancy risk. Although the comparison with biologic-naïve RA patients goes some way towards removing RA status as a potential confounder, the biologic-naïve RA patients had lower levels of disease activity than the TNFi-treated patients. This difference in disease activity could bias the estimates of malignancy risk, however would be most likely to inflate the risk associated with TNFi therapy. Lastly surveillance bias, whereby regular review of RA patients by rheumatologists leads to increased melanoma detection, could have contributed to our finding of increased risk of melanoma in RA patients versus the general population.

Despite the large number of patient years of follow-up malignancy incidence is low in this cohort and the study perhaps lacks power. Larger numbers of patients followed for a longer time period may be necessary to be completely confident that a real increase in malignancy risk in our setting does not exist.

Conclusions {#Sec9}
===========

Our study supports previous reports that have suggested treatment with TNFi is not associated with an overall increased risk of malignancy. It has also verified a previous Australian report of an increased risk of melanoma in RA patients treated with methotrexate compared with the general population. Regular monitoring of RA patients for development of skin cancer is recommended.
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